Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes - PubMed
5 hours ago
- #Pharmacological Treatment
- #Type 2 Diabetes
- #MASLD
- Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes (T2D).
- GLP-1 RAs, dual GIP/GLP-1 RAs, pioglitazone, and SGLT2 inhibitors show benefits in steatohepatitis.
- Semaglutide provides robust evidence for fibrosis benefit, while tirzepatide and dapagliflozin show potential antifibrotic effects.
- Resmetirom and semaglutide are the only agents specifically approved for MASLD.
- Dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists like retatrutide show marked reductions in liver fat.
- Pan-PPAR agonists and FGF21 analogues are advancing through phase 3 development.
- The therapeutic landscape is evolving toward integrated metabolic, hepatic, and cardiovascular risk reduction in T2D and MASLD.